Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 128

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Somapacitan

Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod

Alopecia areata

Not recruiting

Long-Term Study of Ritlecitinib Tosilate for Adults and Adolescents with Alopecia Areata

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
Countries:PolandPoland
  • Participants:0–17 years

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.